The market for erectile dysfunction

Erectile dysfunction ("ED") is the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse.

The ED market is a well-established market with sales of oral PDE5 treatments worth over $4.3bn in 20151. With Viagra® losing patent protection in many countries, Cialis® is now the market leader with sales of $2.3bn worldwide.

The Massachusetts Male Ageing Study ("MMAS") estimated that as many as 52% of men aged 40 or over have some degree of erectile dysfunction. The number of men with erectile dysfunction is rising due to the ageing of the global population and the increased incidence of diabetes.

A market with significant unmet needs

According to independent market research we conducted, 68% of ED patients are not fully satisfied with their treatment and doctors expect that within just one year of treatment initiation, 25% of all ED patients will discontinue therapy.

There is also a subset of erectile dysfunction sufferers who would not be prescribed any of the PDE5 inhibitors due to contraindications with other medications taken by them, including those who have stable angina, a condition treated with nitrate medicines. Due to the mode of action of nitrate medicines, these patients cannot take any of the PDE5 inhibitors.

Market research indicates that only 15%-30% of men with erectile dysfunction consult a doctor. All existing treatments for erectile dysfunction require a prescription from a doctor.

There are clearly significant unmet needs for ED patients.

MED2002 - Our topical treatment for erectile dysfunction

MED2002, our treatment for erectile dysfunction, is a topical gel applied directly to the penis with a rapid onset of action. This topical application has considerable advantages compared with oral treatments in terms of safety and speed of onset.

In a placebo-controlled, double blind, home use, crossover pivotal clinical study completed in 2016, MED2002 showed efficacy, safety and a fast speed of onset. With a superior speed of onset, a compelling safety profile and the potential to switch to over-the-counter, our external market assessment forecasts that MED2002 as a first line therapy could achieve peak annual sales in excess of US$500 million.

Protecting our IP

Futura has both granted patents and a number of further patent applications in relation to its DermaSys® technologies, providing protection to at least 2028.



Source: 1 - 2015 Annual Reports for Pfizer, Lilly and Bayer